INTRODUCTION {#s1}
============

Uniparental disomy (UPD) is a rare event in genetic inheritance that results from two copies of a single chromosome being inherited from one parent ([@MCS004457DANC28]; [@MCS004457DANC17]). To date, approximately 3650 cases have been reported to involve all but four of the 22 autosomes ([@MCS004457DANC019]). The consequences of UPD can be grave, potentially resulting in the homozygous inheritance of pathogenic autosomal recessive variants in case of uniparental *iso*disomy (UPiD) and/or abnormal genomic imprinting, which can happen both in UPiD and uniparental *hetero*disomy (UPhD). The resulting syndromic conditions depend largely on the specific chromosome involved and include a wide range of clinical phenotypes including but not limited to neurodevelopmental disorders, kidney disease, growth irregularities, and metabolic disorders ([@MCS004457DANC28]).

Here, we present a unique case of a female patient with a uniparental paternal isodisomy of Chromosome 12 (UPiD12pat), who presented with mild psychomotor developmental delay, microcephaly, short stature, hypotonia, exercise intolerance, myopia, and progressive transfusion-dependent sideroblastic anemia without major immunological defects. The UPiD12pat isodisomy resulted in homozygous variants in the muscle-specific enzyme 6-phosphofructokinase (*PFKM*) gene and the pseudouridine synthase 1 (*PUS1*) gene driving a multisystem metabolic disorder.

A multitude of metabolic disorders, which mostly have an autosomal recessive inheritance pattern, stem from variants that reduce the formation of ATP. This reduction can occur by impairing a number of different pathways. Enzyme deficiencies that reduce glycolysis and the breakdown of glucose can reduce downstream ATP formation---for example homozygous or compound heterozygous variants in the *PFKM* gene that are linked to glycogen storage disease VII, also called Tarui syndrome (GSD7; MIM \#232800). Variants that specifically impair mitochondrial protein translation can also lead to a loss of ATP through the reduced synthesis of proteins required for oxidative phosphorylation (OXPHOS) in the mitochondria. Variants in mitochondrial tRNAs are reported to drive defects in the central nervous system, muscle, and heart ([@MCS004457DANC35]) as are variants in nuclear genes coding for tRNA synthetases and mitochondrial ribosomal proteins (RPs) ([@MCS004457DANC3]).

Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA) is a rare autosomal recessive metabolic disorder that impairs OXPHOS and iron metabolism ([@MCS004457DANC5]). There are three subtypes of MLASA that are associated with specific variants in genes (found in either nuclear or mitochondrial DNA) coding for proteins that are important for mitochondrial translation and/or OXPHOS. MLASA1 (MIM \#600462) is associated with variants in the *PUS1* gene ([@MCS004457DANC5]), which codes for an enzyme required for the pseudouridylation of nuclear and mitochondrial tRNAs ([@MCS004457DANC21]). MLASA2 (MIM \#613561) is linked to variants in the *YARS2* gene coding for a tyrosine tRNA synthetase enzyme ([@MCS004457DANC27]). In contrast to variants in these nuclear genes involved in mitochondrial translation, MLASA3 (MIM \#500011) is linked to a variant in the *MT-ATP6* gene, which is found on mitochondrial DNA and codes for a subunit of a large enzyme complex called ATP synthase (also known as complex V) that is important for OXPHOS ([@MCS004457DANC4]). Thus, these collective variants linked to MLASA can reduce OXPHOS by decreasing the levels of proteins required for complex formation or by impairing the mitochondrial translation machinery required for generating the proteins involved in complex formation.

Patients with MLASA typically present in late childhood with exercise intolerance, muscle weakness, and in some cases mild intellectual disability and dysmorphic features. Sideroblastic anemia is also often present, a condition defined by the accumulation of iron-laden mitochondria in a ring around the nucleus because of the inability of the cell to incorporate iron into hemoglobin ([@MCS004457DANC15]; [@MCS004457DANC8]; [@MCS004457DANC36]; [@MCS004457DANC12]; [@MCS004457DANC20]; [@MCS004457DANC7]; [@MCS004457DANC16]). This deficiency in iron metabolism is suggested to be the result of impaired mitochondrial translation in MLASA characterized by reduced OXPHOS complex activity and abundance ([@MCS004457DANC26]; [@MCS004457DANC27]; [@MCS004457DANC13]). Because iron sulfur cluster--containing proteins are involved in the electron transport system of the mitochondria, it is likely that the impaired complex formation disturbs the iron homeostasis contributing to the iron overload as observed in sideroblastic anemia ([@MCS004457DANC26]; [@MCS004457DANC30]).

Defects that affect protein translation in the cytoplasm rather than in the mitochondria are also reported to drive anemia in humans. One example is Diamond--Blackfan anemia (DBA; MIM \#105650), an inherited bone marrow failure disorder and red cell aplasia that is linked to haploinsufficiency of several (20 to date) different RP genes, the most common of which is *RPS19* ([@MCS004457DANC31]). One mechanism of action reported to drive the loss of hematopoietic progenitor cells in the bone marrow of DBA patients carrying RP gene variants is the stabilization of the TP53 tumor suppressor protein ([@MCS004457DANC10]). TP53 is normally kept at low levels in cells by binding to the E3-ubiquitin ligase MDM2 protein, the interaction resulting in the constitutive degradation of TP53 ([@MCS004457DANC9]). In the classical model of TP53 activation, cellular stress signals such as DNA damage or nucleolar stress disrupt the MDM2/TP53 interaction, resulting in TP53 stabilization, translocation to the nucleus, and binding to target genes that when expressed either stop the cell cycle, such as p21, and initiate DNA repair or induce apoptosis depending on the level of damage ([@MCS004457DANC34]).

Although the classical TP53 pathway focuses predominantly on the function of the stabilized protein as a transcription factor, it is now widely understood that a cytoplasmic pool of TP53 has an alternate method for promoting apoptosis involving the mitochondria. In this nonnuclear pathway TP53 translocates to the outer mitochondrial membrane in response to stress and interacts with the pro- and anti-apoptotic BCL-2 family members to activate or inhibit them ([@MCS004457DANC32]). For example, in response to DNA damage induced by UV, TP53 directly binds to the prosurvival BCL-2 protein on the outer mitochondrial membrane, displacing it from heterodimers formed with proapoptotic BAX and resulting in BCL-2 degradation. In the absence of BCL-2, BAX proteins are able to oligomerize with other BAX or Bak proteins and form channels in the mitochondrial membrane that allow the release of cytochrome *c*, the subsequent activation of the caspase cascade, and ultimately apoptosis ([@MCS004457DANC38]). Thus, the ratio of BCL-2:BAX proteins has emerged as an important indicator as to whether a cell is being driven toward survival or apoptosis ([@MCS004457DANC18]; [@MCS004457DANC25]).

This study reports a patient with a multisystem metabolic disorder involving early-onset MLASA caused by an extremely rare UPiD event that resulted in the inheritance of homozygous pathogenic variants in genes reported to drive metabolic disease. The subsequent analysis on primary patient cells was performed in order to test how these variants affected cellular function focusing on mitochondrial translation and the downstream effects of its impairment in the context of the TP53 pathway.

RESULTS {#s2}
=======

A Homozygous Variant c.1122C \> G in *PUS1* Identified in a Patient with MLASA {#s2a}
------------------------------------------------------------------------------

Here, we report a young female patient who was referred to the clinic at 4 yr of age. She presented with mild psychomotor developmental delay (IQ ∼ 80), microcephaly (\<−2,5 SD), short stature (−3 SD), hypotonia, exercise intolerance, myopia, and progressive transfusion-dependent sideroblastic anemia without major immunological defects (see [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004457/-/DC1) for complete blood count). She was the only child of nonconsanguineous Caucasian parents.

Clinical examination at first presentation showed mild facial dysmorphisms with upslanting palpebral fissures, hypertelorism, hypoplastic alae nasi, a smooth philtrum, small chin, and cup-shaped and low implanted ears. Furthermore, there was a tapering of the fingers, bilateral clinodactyly of the fifth digits, vitiligo, and mild eczema. Biochemical investigations revealed a slightly elevated lactate in the blood with no amino acid abnormalities (data not shown). At the age of 7 yr and 4 mo the patient received a stem cell transplantation for her sideroblastic anemia and unexpectedly died because of a viral gastroenteritis with metabolic dysregulation. No permission for autopsy was gained and no muscle biopsy was performed during her life or after she passed away.

Initial genetic testing showed no abnormalities in karyotyping (46, XX) or in microarray CGH analysis. A mitomycin C test excluded Fanconi anemia (FA; MIM \#227650). The presence of myopathy and bone marrow failure suggested a possible diagnosis of Pearson syndrome; however, targeted sequencing of mtDNA excluded this possibility. DBA was also considered; however, targeted sequencing of *RPS19* and *RPS24* (commonly mutated genes in DBA \[[@MCS004457DANC6]\]) and at the time the only RP genes that were part of the targeted sequencing panel) revealed these genes to be wild type. Genes (*SHOX*, *FGFR3*, *NBS1*) linked to Nijmegen breakage syndrome (NBS; MIM \#251260) and several sideroblastic anemia (SIDBA1; MIM \#300751) genes (*SLC25A38*; *GLR5*, *STEAP3*, *ABCB7*, *ALAS2*) were also sequenced and found to be wild type.

Trio whole-exome sequencing (WES) was then performed after the targeted sequencing of the disease genes described above. This revealed homozygosity of several variants on Chromosome 12 of the patient ([Fig. 1](#MCS004457DANF1){ref-type="fig"}A; [Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004457/-/DC1)). The father of the patient was found to be a heterozygous carrier of these variants, and the mother\'s DNA only revealed the wild type. The absence of heterozygous variants on Chromosome 12 suggested the occurrence of a paternal UPiD in which the patient inherited two identical copies of one Chromosome 12 from her father ([Fig. 1](#MCS004457DANF1){ref-type="fig"}A,B; [Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004457/-/DC1)). Two of these variants were identified as potentially pathogenic: (1) a previously unreported homozygous variant in the *PUS1* gene (c.1122C \> G, p.Tyr374\*; NM_025215.5) which is associated with mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA1; MIM \#600462) and (2) a homozygous splice site variant in *PFKM* (c.237 + 1G \> A, NM_000289.5), which is associated with GSD7, also called Tarui syndrome ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004457/-/DC1)).

![Identified homozygous variant c.1122C \> G reduces *PUS1* mRNA and protein levels. (*A*) The percentage of variant reads for all variants on Chromosome 12 identified by whole-exome sequencing (*left*). This demonstrates an absence of heterozygous variants, which was not seen for other chromosomes---for example, Chromosome 13 (*right*). (*B*) Pedigree of the affected individual illustrating paternal isodisomy. (*C*) Sanger sequencing of fibroblasts from the affected individual illustrating the homozygous C \> G point mutation introducing a nonsense stop codon. (*D*) Quantitative polymerase chain reaction (qPCR) measuring mRNA expression of *PUS1* in healthy control (black) and the affected individual (gray) in fibroblasts, normalized to β-actin mRNA. Data are represented as the mean (*N* = 3), (\*\*) *P* \< 0.005 as calculated by a two-tailed Student\'s *t*-test. (*E*) Western blot showing the reduced PUS1 protein levels in fibroblasts derived from the affected individual compared to a healthy control. All western blots shown are representative of at least three independent experiments. (*F*) Confocal microscopy of fibroblasts illustrating the localization of PUS1 (green), mitochondria demarked by TOMM20 (red), and an overlay (yellow) including DAPI (blue) staining.](MCS004457Dan_F1){#MCS004457DANF1}

Sanger sequencing performed in patient fibroblasts confirmed the homozygous nonsense variant in *PUS1* (c.1122C \> G) predicted to replace the codon for a tyrosine at position 374 with a TAG stop codon ([Fig. 1](#MCS004457DANF1){ref-type="fig"}C) and the splice site variant in *PFKM* ([Supplemental Fig. S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004457/-/DC1)). Although the allele frequency for the *PFKM* variant (ClinVar \[<https://www.ncbi.nlm.nih.gov/clinvar>\] accession number VCV000189239) is calculated to be between 0.00006 and 0.00008 (Trans-Omics for Precision Medicine and Exome Aggregation Consortium, respectively), variants in the *PUS1* gene are exceptionally rare. Only 15 individuals to date have been reported in the literature with *PUS1* variants (excluding this study), including one individual who was erroneously diagnosed with DBA ([@MCS004457DANC31]) (see [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004457/-/DC1) for full description of previously reported *PUS1* variants). The new *PUS1* variant information was submitted to ClinVar and has the accession number SCV000995055 (see [Table 1](#MCS004457DANTB1){ref-type="table"} for variant details).

###### 

Description of variants described in this study

  Gene      Chromosome  HGVS DNA reference   HGVS protein reference   Variant type                Predicted effect   dbSNP/db Var ID   Genotype     ClinVar ID
  -------- ------------ -------------------- ------------------------ --------------------------- ------------------ ----------------- ------------ --------------
  *PFKM*        12      c.237 + 1G \> A      N/A                      Single-nucleotide variant   Splice donor       rs202143236       Homozygous   VCV000189239
  *PUS1*        12      c.1122C \> G         p.Tyr374\*               Single-nucleotide variant   Nonsense           N/A               Homozygous   SCV000995055

Quantitative PCR (qPCR) analysis of primary fibroblasts derived from the affected individual revealed a significant reduction in *PUS1* mRNA levels compared to fibroblasts from a healthy control ([Fig. 1](#MCS004457DANF1){ref-type="fig"}D). This was confirmed by western blotting using an antibody recognizing both PUS1 protein isoforms in the healthy control but not in patient cells ([Fig. 1](#MCS004457DANF1){ref-type="fig"}E). Another primary antibody recognizing a different epitope of PUS1 also showed little remaining PUS1 protein in the same fibroblasts ([Supplemental Fig. S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004457/-/DC1)). We also measured the levels of *PFKM* mRNA in healthy control and patient fibroblasts by qPCR. We did not detect any *PFKM* mRNA in either cell line, confirming our expectation that *PFKM* expression is restricted to muscle ([@MCS004457DANC24]) and should not be found in dermal fibroblasts ([Supplemental Fig. S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004457/-/DC1)).

Confocal microscopy analysis of healthy control fibroblasts with antibodies against PUS1 proteins and TOMM20 proteins (which are used as markers of the mitochondria) revealed the expected colocalization of PUS1 with the nucleus and mitochondria (shown previously with HA-tagged PUS1 constructs \[[@MCS004457DANC12]\]). In contrast, negligible staining of PUS1 was detected in the patient fibroblasts, with a complete loss of nuclear PUS1 staining and no observable colocalization with TOMM20 and the mitochondria ([Fig. 1](#MCS004457DANF1){ref-type="fig"}F). This result is in line with the observation that there is little remaining PUS1 mRNA and no detectable PUS1 protein in the primary fibroblasts derived from the affected individual.

Absence of PUS1 Likely Impairs Mitochondrial Translation {#s2b}
--------------------------------------------------------

Because PUS1 is required for the proper pseudouridylation of tRNAs necessary for efficient mitochondrial translation, we assessed the protein levels of succinate dehydrogenase complex (SDHA) and cytochrome c oxidase subunit I (MTCO1). Although both SDHA and MTCO1 proteins are localized to mitochondria and are required subunits for the formation of OXPHOS complexes, only MTCO1 is encoded by a mitochondrial DNA gene. We observed a significant reduction in MTCO1 expression in the fibroblasts carrying the *PUS1* variant, whereas the SDHA levels in these cells remained equal to the levels in healthy control cells ([Fig. 2](#MCS004457DANF2){ref-type="fig"}A,B). These results suggest that in line with previous reports noted above ([@MCS004457DANC12]), the loss of PUS1 protein specifically drives a reduction of mitochondrial protein translation.

![The PUS1 variant specifically impairs mitochondrial translation. (*A*) Western blot showing the protein levels of the nuclear-encoded SDHA compared to the mitochondrial-encoded MTCO1 in fibroblasts carrying the PUS1 p.Tyr374\* variant or derived from a healthy control. (*B*) Quantification of the results in *A*. The levels of SDHA (*left*) and MTCO1 (*right*) in fibroblasts from the affected individual (gray) and healthy control (black) normalized to β-actin. Protein levels of MTCO1 are significantly reduced in cells from affected individual compared to healthy control, whereas the SDHA protein levels remain stable. Data are represented as the mean (*N* = 3), (\*\*\*\*) *P* \< 0.00005 as calculated by a two-tailed Student\'s *t*-test.](MCS004457Dan_F2){#MCS004457DANF2}

Fibroblasts Carrying the *PUS1* Variant Reveal Destabilization and Hypersensitivity to UVC Exposure {#s2c}
---------------------------------------------------------------------------------------------------

Because defects in the cytoplasmic translation are widely reported to activate the TP53 pathway ([@MCS004457DANC10]), we measured TP53 stabilization in fibroblasts carrying the *PUS1* c.1122C \> G variant in order to determine if impaired mitochondrial translation also affects the pathway. For these experiments *PUS1* variant and healthy control fibroblasts were untreated or exposed to 50 J/m^2^ UVC radiation. Twenty-four hours after exposure cells were collected for analysis of the levels of proteins involved in the TP53 activation pathway ([Fig. 3](#MCS004457DANF3){ref-type="fig"}A). The levels of TP53 were significantly increased in patient fibroblasts compared to healthy control cells under basal conditions ([Fig. 3](#MCS004457DANF3){ref-type="fig"}A,B). Moreover, exposing cells to UVC revealed a much stronger induction of TP53 stabilization compared to what was observed in healthy control cells exposed to UVC ([Fig. 3](#MCS004457DANF3){ref-type="fig"}A,B).

![Cells carrying the PUS1 p.Tyr374\* variant stabilize TP53 and alter mitochondrial protein BCL-2 and BAX levels. (*A*) Western blot showing the protein levels of TP53, p21, BCL-2, and BAX in fibroblasts derived from a healthy control or the affected individual upon 50 J/m^2^ UVC exposure after 24 h. (*B*) Protein levels of TP53 were significantly increased in cells from affected individual (gray) under basal conditions (−UV) and further increased upon UVC exposure (+UV) compared to control cells (black). (*C*) Protein levels of p21 were significantly lower in cells from the affected individual under both conditions; however, p21 was still induced upon UVC exposure. (*D*) BCL-2 and (*E*) BAX protein levels were reduced in cells from the affected individual under both conditions. (*F*) The ratio of BAX:BCL-2 is shown to remain stable in cells from affected individual and control cells under both conditions. Data are represented as the mean (*N* = 3), (\*) *P* \< 0.05, (\*\*) *P* \< 0.005, (\*\*\*) *P* \< 0.0005 as calculated by a two-tailed Student\'s *t*-test.](MCS004457Dan_F3){#MCS004457DANF3}

The cyclin-dependent kinase inhibitor p21 (*WAF1/CDKN1A*) is a nuclear gene and direct target of TP53 that is up-regulated in response to several kinds of cellular stress ([@MCS004457DANC11]). Despite the increased levels of TP53 under basal conditions in the patient fibroblasts compared to healthy control cells, levels of p21 in the same conditions were markedly reduced in the patient cells ([Fig. 3](#MCS004457DANF3){ref-type="fig"}A,C). In both patient and healthy control cells a relatively similar induction of p21 protein is observed as a result of UVC exposure, suggesting that the TP53/p21 pathway remains unimpaired in the mutant cells ([Fig. 3](#MCS004457DANF3){ref-type="fig"}A,C). These results suggest that although an increase in TP53 stabilization is observed in cells carrying the *PUS1* variant, this pool of TP53 is not targeting and up-regulating the classical *p21* gene target in the nucleus.

We next measured levels of the outer mitochondrial membrane proteins BCL-2 and BAX. The levels of both these proteins were reduced in the cells carrying the *PUS1* variant, both with or without UVC ([Fig. 3](#MCS004457DANF3){ref-type="fig"}A,D,E). Interestingly, the concomitant decrease of BCL-2 and BAX results in a relatively unchanged BAX:BCL-2 ratio in the cells carrying the *PUS1* variant compared to healthy control cells ([Fig. 3](#MCS004457DANF3){ref-type="fig"}F), whereas an increase of this ratio would have been suggestive of apoptosis ([@MCS004457DANC38]; [@MCS004457DANC37]). Taken all together, these results suggest that although cells carrying the *PUS1* variant stabilize TP53 under basal conditions, this does not result in the up-regulation of target genes such as *p21*. However, the degradation of BCL-2 in the mutant cells under basal conditions suggests destabilization of the mitochondria. The concomitant reduction of BAX suggests that the cells carrying the *PUS1* variant are able to equilibrate the BAX:BCL-2 ratio by reducing BAX levels in the outer mitochondrial membrane, perhaps as a mechanism to prevent cytochrome *c* release from the mitochondria and evade apoptosis. This hypothesis is supported by electron micrographs of healthy control and patient fibroblasts showing that stress-induced changes in mitochondria, such as their fragmentation and disorganization/swelling of their cristae ([@MCS004457DANC23]), are only evident in the *PUS1* mutant cells 24 h after UVC exposure, and no major changes are evident in cells at basal levels ([Fig. 4](#MCS004457DANF4){ref-type="fig"}).

![Electron microscopy of fibroblasts with and without UVC exposure. (*A*) Patient (PUS1 p.Tyr374\*) (*lower* panels) and healthy control (*upper* panels) fibroblasts show no morphological difference at basal level (*left* panels). Twenty-four hours after exposure to 50 J/m^2^ UVC (+UV, right panels), note the increased fragmentation of mitochondria in the cells carrying the *PUS1* variant in the dashed box outline labeled R. (*B*) Enlarged images of UVC-treated fibroblasts from a healthy control on the left (L) and carrying the PUS1 p.374Tyr\* variant on the right (R). White arrowheads indicate swollen cristae.](MCS004457Dan_F4){#MCS004457DANF4}

DISCUSSION {#s3}
==========

This study describes a young female child who was diagnosed with mitochondrial myopathy, lactic acidosis, and sideroblastic anemia type 1 (MLASA1) and with glycogen storage disease VII (GSD7) resulting from a paternal uniparental isodisomy of Chromosome 12 (UPiD12pat) event. A UPD is a rare event and it usually arises as a result of rescue of a trisomy or monosomy in a zygote ([@MCS004457DANC28]; [@MCS004457DANC17]). In the case of a trisomy rescue, one of the three chromosomes is lost, and when the two remaining chromosomes originate from the same parent, the result is a UPD. As recombination occurs during meiosis, these chromosomes have parts of heterodisomy (two different copies of the same parent) and parts of isodisomy (same copies of the same parent) ([@MCS004457DANC2]). Because the patient carried two completely identical copies of the paternal Chromosome 12, we suspect that the mode of UPD formation in this case was the rescue of a monosomy, by duplication of the single paternal chromosome in the zygote, resulting in a complete UPiD.

The UPiD12pat resulted in inheritance of homozygous pathogenic variants: one previously reported variant (c.237 + 1G \> A) in *PFKM* that impairs glycolysis and an unreported early stop codon (c.1122C \> G; p.Tyr374\*) in the *PUS1* gene. The identification of this latter homozygous variant makes this the 16th case known with MLASA1 linked to *PUS1* (see [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004457/-/DC1)). Primary fibroblasts showed decreased *PUS1* mRNA expression and protein levels compared to healthy control cells, suggesting the mRNA is subject to nonsense-mediated decay ([Fig. 1](#MCS004457DANF1){ref-type="fig"}D--F). Cells carrying the variant and depleted PUS1 protein levels revealed reduced levels of a specific mitochondrial-encoded protein, whereas levels of a nuclear-encoded protein remained unchanged, strongly suggesting that the variant is impairing mitochondrial translation ([Fig. 2](#MCS004457DANF2){ref-type="fig"}). In addition, primary patient cells revealed altered levels of BAX, BCL-2, and TP53 proteins suggestive of destabilization, especially upon exposure to UV ([Fig. 3](#MCS004457DANF3){ref-type="fig"}). The mitochondria in the patient cells also reveal a more abnormal and fragmented morphology compared to healthy control cells upon UV exposure ([Fig. 4](#MCS004457DANF4){ref-type="fig"}).

In contrast to the formerly described individuals who mostly presented with MLASA1 in late childhood ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004457/-/DC1)), this patient presented at an early childhood age with a typical MLASA1 phenotype (e.g., exercise intolerance, lactic acidosis, and sideroblastic anemia), which are all reported features in patients with *PUS1* variants ([@MCS004457DANC15]; [@MCS004457DANC8]; [@MCS004457DANC36]; [@MCS004457DANC12]; [@MCS004457DANC20]; [@MCS004457DANC7]; [@MCS004457DANC16]). However, it is highly likely that her clinical phenotype, such as the exercise intolerance and elevated lactate, was exacerbated by the second inherited homozygous variant (c.237 + 1G \> A) in the splice site of the *PFKM*. In fact, this particular variant has been reported with some frequency in patients with GSD7. This disease often but not always results in exercise intolerance, myopathy, and red cell hemolysis ([@MCS004457DANC24]). In fact, it is suspected that the clustering of reported variants linked to GSD7 disease may reflect a referral bias because individuals carrying pathogenic variants often have such mild clinical phenotypes that they do not seek medical treatment ([@MCS004457DANC24]). Nonetheless, with the individual reported in this study we cannot attribute the clinical phenotype entirely to the *PUS1* variant, and it seems very likely that both variants contributed to the severity of her condition. However, for the molecular biology studies in patient fibroblasts, the expression of *PFKM* (being a muscle-specific gene \[[@MCS004457DANC33]\]) in both healthy control and patient cells is negligible, which allows us to focus more exclusively on the downstream effects of *PUS1* variant.

The reductions of the mitochondrial BCL-2 and BAX proteins in the cells carrying the *PUS1* variant strongly suggest destabilization of the mitochondria, in line with the observation that the variant likely affects mitochondrial but not cytoplasmic translation ([Fig. 2](#MCS004457DANF2){ref-type="fig"}). Although it is known that PUS1 can function both in the cytoplasm and mitochondria, it is possible that the redundancy of the other PUS enzymes (PUS2-7) is able to compensate for the loss of PUS1 in the cytoplasm but not the mitochondria ([@MCS004457DANC21]; [@MCS004457DANC29]). However, we cannot rule out the possibility that the loss of PUS1 impairs cytoplasmic translation subtly in a way that is undetectable with our experimental methods.

The unchanged ratio between the reduced BCL-2 and BAX proteins in the cells carrying the *PUS1* variant compared to healthy control cells is also an interesting observation that we cannot fully explain ([Fig. 3](#MCS004457DANF3){ref-type="fig"}F). Reductions of BCL-2 alone in response to cellular stress would drive the formation of channels in the outer mitochondrial membrane and the release of cytochrome *c*, which would then go on to initiate caspase cleavage and apoptosis ([@MCS004457DANC38]; [@MCS004457DANC37]; [@MCS004457DANC14]). Thus, like the reduction of p21, perhaps the cells carrying the *PUS1* variant have devised a mechanism to evade apoptosis by concomitantly reducing levels of BAX and maintaining an equal BAX:BCL-2 ratio.

TP53 stabilization is known to be linked to syndromes with impaired cytoplasmic translation such as DBA, and cell-based studies show that variants driving this increase of TP53 also result in an increase of p21 at basal levels ([@MCS004457DANC1]; [@MCS004457DANC22]). In contrast, the fibroblasts used for the current study revealed a reduction of p21 in cells carrying the *PUS1* variant compared to healthy control cells, although both healthy control and *PUS1* mutant cell lines revealed the expected increase of p21 levels upon exposure to UVC ([Fig. 3](#MCS004457DANF3){ref-type="fig"}A,C). These results suggest that the classical TP53 pathway response to DNA damage remains undisturbed in cells carrying the *PUS1* variant, and also suggest that p21 levels are kept at low levels perhaps as a way for the cell cycle to proceed unimpeded by a mechanism that remains unknown. However, it is important for us to note here that we cannot be entirely sure as to what specifically is driving the TP53 stabilization in the patient cells. Because there are previous reports linking inherited mutations that drive mitochondrial disease to an increased susceptibility of cells to apoptosis ([@MCS004457DANC19]), it seems likely that this augmented TP53 stabilization is due to the *PUS1* variant. That said, we cannot rule out that this is an effect of general genomic instability driven by the UPiD or to some other unknown variable. Moreover, it remains unclear what the downstream clinical impact is resulting from the observed increase in TP53 stabilization in the fibroblasts. Although similar augmented TP53 stabilization has been observed---in bone marrow failures, syndromes linked to variants that impair cytoplasmic translation (such as DBA)---the pathophysiology explaining these genotype:phenotype correlations remains to be fully solved.

In conclusion, this study reports a rare UPiD event driving a complex multisystem metabolic disorder that resulted from the paternal inheritance of two homozygous pathogenic variants, one previously reported in *PFKM* and one unreported truncating variant in *PUS1*. The effects of these two variants on glycolysis and mitochondrial translation likely are responsible for driving the severity of the clinical phenotype. Moreover, primary cells from the patient suggest that there may be a link between impaired mitochondrial translation and the TP53 pathway, an area that will be very interesting for future research.

METHODS {#s4}
=======

Cell Culture {#s4a}
------------

Primary skin fibroblasts from patients and healthy controls were obtained from a punch biopsy on the upper arm and cultured on DMEM (Bio-Whittaker) medium supplemented with 10% fetal bovine serum (Bio-Whittaker), 25 mM HEPES buffer (Bio-Whittaker), 100 U/mL penicillin, 100 µg/mL streptomycin (Life Technologies), and 250 ng/mL Fungizone (Life Technologies). Cells were cultured at 37°C with 5% CO~2~.

Whole-Exome Sequencing {#s4b}
----------------------

WES was performed by the molecular DNA genetic technicians of the Department of Clinical Genetics of the Amsterdam UMC, Amsterdam. Whole-exome capture was performed using SeqCap EZ Human Exome Library v3.0 (Roche NimbleGen). The resulting enriched libraries were sequenced on a HiSeq 2500 platform (Illumina) according to the manufacturer\'s recommendations for paired-end 101-bp reads. A total of 44,308,329 reads were obtained from the proband 41,606,886 from the father and 37,140,533 from the mother. Alignment of sequence reads to human reference genome (hg19) was done using BWAMEM (bio-bwa.sourceforge.net/), and variants were called using the GATK3.2 software package ([www.broadinstitute.org/gatk/](www.broadinstitute.org/gatk/)). Mean coverage was 70-fold for the proband, and 86% of the exome was covered with more than 20 reads. Filtering of variants was done using Cartagenia Bench Lab NGS (Agilent). Variants with fewer than five reads, a frequency of more than 1% in public (ESP, dbSNP, 1KG) and/or in-house databases were excluded. De novo, homozygous, or compound heterozygous variants present in exons or within ±6 nt in the intron were evaluated. This revealed homozygosity for the variant c.1122C \> G, p.Tyr374\* in *PUS1* (NM_025215.5) and variant c.237 + 1G \> A in *PFKM* (NM_000289.5). Coverage at these variants was 110-fold and 54-fold, respectively. Both variants were confirmed by Sanger sequencing. Explicit permission for making the exome sequencing data publicly available was not granted.

Sanger Sequencing {#s4c}
-----------------

Confirmation of the variants found by WES was done using Sanger sequencing. Primers were developed to amplify exon 5 of PUS1 (primer sequences available on request). After PCR products were sequenced using Bigdye v1.1 chemistry and an ABI3100 sequencer (Life Technologies). Sequences were analyzed using CodonCode Aligner (CodonCode Corporation).

qPCR {#s4d}
----

TRIzol Reagent (Sigma-Aldrich) was used to isolate RNA from fibroblasts. Genomic DNA was eliminated, and cDNA was made by the use of QuantiTect Reverse Transcription Kit (QIAGEN). qPCR samples were prepared with SYBR green (Roche), and qPCR was performed on the LightCycler 480 device (Roche).

The primers were *PUS1* (Fw: CATGCAGAGGAATGTCGGGT, Rev: AATCAGCCACACCTTCAGGG) and β-actin (Fw: AGTCATTCCAAATATGAGATGCGTT, Rev: GCTATCACCTCCCCTGTGTG).

Western Blotting {#s4e}
----------------

Protein was isolated from fibroblasts with the use of RIPA lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100) supplemented with Complete mini protease inhibitor (Roche). Subsequently, samples were sonicated to ensure complete lysis. The protein concentrations were determined using the BCA Protein Assay (Thermo Scientific). Protein samples were prepared with LDS sample buffer (NuPage, Invitrogen) and sample reducing agent (NuPage, Invitrogen). Protein samples were loaded onto a 4%--12% Tris-Bis Protein Gel (NuPage, Invitrogen). Gels were transferred to a nitrocellulose membrane using the iBlot Dry Blotting System. Membranes were blocked with 3% milk in PBS-T (0.1% Tween-20) and incubated with primary (O/N, 4°C) and secondary (1 h, RT) antibodies.

The primary antibodies were PUS1 (NBP1-32902, Novus Biologicals), PUS1 (sc-376443, Santa Cruz), MTCO1 (ab14705, Abcam), SDHA (ab14715, Abcam), TP53 (sc-6243, Santa Cruz), BCL-2 (ab692-500, Abcam), BAX (\#2772, Cell Signaling), and β-actin (A5441, Sigma-Aldrich).

The secondary antibodies were IRDye 800CW goat anti-rabbit (925-32211, LI-COR), IRDye 800CW goat anti-mouse (925-32210, LI-COR), and IRDye 680RD donkey anti-mouse (925-68072, LI-COR).

Confocal Microscopy {#s4f}
-------------------

Cells were fixed with 2% PFA-PBS, permeabilized with 0.1% triton-PBS, and blocked with 1% BSA-PBS buffer. Primary antibody was prepared in 1% BSA-PBS (1:100) and secondary in 1% PBS (1:200). Cells were washed and mounted with Prolong Gold antifade reagent with DAPI (Invitrogen p36935). The primary antibodies were PUS1 (sc-376443, Santa Cruz), and TOMM20 (ab70699, Abcam). The secondary antibodies were rabbit biotin (E0432, Dako), FITC (11-4317-87, eBioscience), and Alexa Fluor 633 (A21052, Life Technologies)

Transmission Electron Microscopy Imaging {#s4g}
----------------------------------------

Fibroblasts were exposed to UVC irradiation (50 J/m^2^) and incubated for 24 h. After treatment cells were fixated O/N with McDowells fixative; 1% glutaraldehyde, 4% paraformaldehyde in 0.1 M phosphate buffer. After washing with phosphate buffer the specimens were postfixed with a solution of 1% OsO~4~ in water. Subsequently, the specimens were dehydrated in an ethanol series and embedded in epoxy resin (LX112). For electron microscopic analysis ultrathin (70-nm) sections of the samples were cut with a diamond knife, collected on formvar-coated grids, and counterstained with uranyl acetate and lead citrate. All samples were examined and photographed in a FEI Tecnai T12 transmission electron microscope at the Electron Microscopy Centre Amsterdam.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The *PUS1* variant was deposited in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar>) under accession number SCV000995055.
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